An interventional study of Brivaracetam and Levetiracetam in Epilepsy, sponsored by RESnTEC, Institute of Research. Completed at 1 site in Pakistan. Open to participants aged 1 Month to 14 Years. Per ClinicalTrials.gov, last updated 2025-09-09.
Sponsored by RESnTEC, Institute of Research · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies testing brivaracetam in Epilepsy — 1 open to participants now, 2 under way, 1 of them phase 3. brivaracetam · Epilepsy.
Among the 34 studies testing brivaracetam in Epilepsy, this one is the 16th largest by enrollment, is one of 2 that started in 2024, is the only one with no phase, and was the 34th registered.
1,850 studies on the registry are indexed under Epilepsy; 418 are open to participants now.
Browse Epilepsy studies →1 of the 34 studies testing brivaracetam in Epilepsy is open now, in 1 country. Recruiting first, the newest first:
Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. · Sites in China
Ages 18–55 · Healthy volunteers
By country, each count listing its studies:
brivaracetam: first FDA approval 2016 (BRIVIACT), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 284 Epilepsy studies recruiting now, 113 (40%) set no upper age limit and 148 (52%) stop at 75 or younger; 138 take children under 18; 54 take healthy volunteers.
This study: 1 Month to 14 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 2 started in 2024.
This study's enrollment of 102 is above the median of 50 across 1,240 interventional studies indexed under Epilepsy.
Median enrollment 94 across the 34 interventional studies. Of the 31 that completed or were terminated, 23 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 34 have an industry lead sponsor. The 10 most frequent:
RESnTEC, Institute of Research is the lead sponsor of 16 studies on the registry; 2 are open to participants now.
RESnTEC, Institute of Research has 1 study filed under Epilepsy — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 34 studies testing brivaracetam in Epilepsy, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Despite increasing clinical use of both agents, there is a paucity of head-to-head comparative data on the safety and efficacy of brivaracetam versus levetiracetam as initial monotherapy in children. The present study was therefore designed to compare the safety and efficacy of oral brivaracetam and levetiracetam as monotherapy in children aged one month to 14 years with newly diagnosed epilepsy.
Most existing studies have focused on adjunctive use or refractory epilepsy, while evidence in treatment-naïve pediatric populations remains sparse. Addressing this gap is critical, as early and effective seizure control can substantially influence long-term neurodevelopmental outcomes. By evaluating seizure outcomes, tolerability, and adverse effect profiles, this study aims to provide evidence to guide clinicians in selecting the most appropriate first-line anti-seizure medication (ASM) for pediatric patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients were given oral brivaracetam in a dose of 1-2 mg/kg/day in two divided doses, titrated to a maximum of 5 mg/kg/day based on clinical response and tolerability.
Drug: Brivaracetam
Oral levetiracetam was initiated at a dose of 10-20 mg/kg/day in two divided doses, with gradual escalation up to 60 mg/kg/day if needed.
Drug: Levetiracetam
Brivaracetam was initiated at a dose of 1-2 mg/kg/day in two divided doses, titrated to a maximum of 5 mg/kg/day based on clinical response and tolerability.
Levetiracetam was initiated at a dose of 10-20 mg/kg/day in two divided doses, with gradual escalation up to 60 mg/kg/day if needed.
Cessation of seizures
Cessation of seizures was labeled "yes" when a patient remained seizure free.
Time frame: Up to 3 months
Adverse events
Labeled "yes" if any treatment-related adverse events reported.
Time frame: Up to 3 months
Plan to share: No — Data can be shared on a reasonable request.
No publications or documents are linked to this record.
Ran from Aug 2024 to primary completion in Jul 2025, 11 months.
Of 339 non-industry interventional studies with no phase under Epilepsy, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 77. This study's 11 months is below that.
Counting every sponsor, half of 360 studies reached it within 42 months; a quarter within 19 and three quarters within 77.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Brivaracetam · Levetiracetam
RESnTEC, Institute of Research